TY - JOUR
T1 - Bile Acid Modifications at the Microbe-Host Interface
T2 - Potential for Nutraceutical and Pharmaceutical Interventions in Host Health
AU - Joyce, Susan A.
AU - Gahan, Cormac G.M.
N1 - Publisher Copyright:
Copyright © 2016 by Annual Reviews. All rights reserved.
PY - 2016/2/28
Y1 - 2016/2/28
N2 - Bile acids have emerged as important signaling molecules in the host, as they interact either locally or systemically with specific cellular receptors, in particular the farnesoid X receptor (FXR) and TGR5. These signaling functions influence systemic lipid and cholesterol metabolism, energy metabolism, immune homeostasis, and intestinal electrolyte balance. Through defined enzymatic activities, the gut microbiota can significantly modify the signaling properties of bile acids and therefore can have an impact upon host health. Alterations to the gut microbiota that influence bile acid metabolism are associated with metabolic disease, obesity, diarrhea, inflammatory bowel disease (IBD), Clostridium difficile infection, colorectal cancer, and hepatocellular carcinoma. Here, we examine the regulation of this gut-microbiota-liver axis in the context of bile acid metabolism and indicate how this pathway represents an important target for the development of new nutraceutical (diet andor probiotics) and targeted pharmaceutical interventions.
AB - Bile acids have emerged as important signaling molecules in the host, as they interact either locally or systemically with specific cellular receptors, in particular the farnesoid X receptor (FXR) and TGR5. These signaling functions influence systemic lipid and cholesterol metabolism, energy metabolism, immune homeostasis, and intestinal electrolyte balance. Through defined enzymatic activities, the gut microbiota can significantly modify the signaling properties of bile acids and therefore can have an impact upon host health. Alterations to the gut microbiota that influence bile acid metabolism are associated with metabolic disease, obesity, diarrhea, inflammatory bowel disease (IBD), Clostridium difficile infection, colorectal cancer, and hepatocellular carcinoma. Here, we examine the regulation of this gut-microbiota-liver axis in the context of bile acid metabolism and indicate how this pathway represents an important target for the development of new nutraceutical (diet andor probiotics) and targeted pharmaceutical interventions.
KW - Bile acid
KW - Cholesterol
KW - Microbiota
KW - Obesity
KW - Probiotic
UR - https://www.scopus.com/pages/publications/84959882996
U2 - 10.1146/annurev-food-041715-033159
DO - 10.1146/annurev-food-041715-033159
M3 - Article
C2 - 26772409
AN - SCOPUS:84959882996
SN - 1941-1413
VL - 7
SP - 313
EP - 333
JO - Annual Review of Food Science and Technology
JF - Annual Review of Food Science and Technology
ER -